Diagnostic accuracy of the Xpert CT/NG and OSOM Trichomonas Rapid assays for point-of-care STI testing among young women in South Africa: a cross-sectional study.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
19 02 2019
Historique:
entrez: 21 2 2019
pubmed: 21 2 2019
medline: 26 3 2020
Statut: epublish

Résumé

Syndromic management of sexually transmitted infections (STIs) omits asymptomatic infections, particularly among women. Accurate point-of-care assays may improve STI care in low- and middle-income countries (LMICs). We aimed to evaluate the diagnostic performance of the Xpert Diagnostic evaluation conducted as part of a prospective cohort study (CAPRISA 083) between May 2016 and January 2017. One large public healthcare facility in central Durban, KwaZulu-Natal, South Africa PARTICIPANTS: 247 women, aged 18-40 years, attending for sexual and reproductive services to the clinic. Pregnant and HIV-positive women were excluded. Diagnostic performance of the Xpert CT/NG and OSOM TV assays against the laboratory-based Anyplex II STI-7 Detection. All discordant results were further tested on the Fast Track Diagnostics (FTD) STD9 assay. We obtained vaginal swabs from 247 women and found 96.8% (239/247) concordance between Xpert and Anyplex for CT and 100% (247/247) for NG. All eight discrepant CT results were positive on Xpert, but negative on Anyplex. FTD STD9 confirmed three positive and five negative results, giving a confirmed prevalence of CT 15.0% (95% CI 10.5 to 19.4), NG 4.9% (2.2-7.5) and TV 3.2% (1.0-5.4). Sensitivity and specificity of Xpert CT/NG were 100% (100-100) and 97.6% (95.6-99.7) for CT and 100% (100-100) and 100% (100-100) for NG. The sensitivity and specificity of OSOM TV were 75.0% (45.0-100) and 100% (100-100). The Xpert CT/NG showed high accuracy among young South African women and combined with the OSOM TV proved a useful tool in this high HIV/STI burden setting. Further implementation and cost-effectiveness studies are needed to assess the potential role of this assay for diagnostic STI testing in LMICs. NCT03407586; Pre-results.

Identifiants

pubmed: 30782948
pii: bmjopen-2018-026888
doi: 10.1136/bmjopen-2018-026888
pmc: PMC6367982
doi:

Banques de données

ClinicalTrials.gov
['NCT03407586']

Types de publication

Clinical Trial Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e026888

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: Cepheid Inc loaned two 4-module GeneXpert machines to the study team free-of-charge, but had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Références

Fam Pract. 2018 Jul 23;35(4):475-480
pubmed: 29385437
J Clin Microbiol. 2017 Dec;55(12):3563-3565
pubmed: 29021154
BMJ Open. 2018 Feb 21;8(2):e018132
pubmed: 29467132
PLoS One. 2016 May 12;11(5):e0155383
pubmed: 27171270
PLoS One. 2018 Apr 24;13(4):e0196209
pubmed: 29689080
PLoS Med. 2017 Jun 27;14(6):e1002330
pubmed: 28654670
J Clin Microbiol. 2013 Jun;51(6):1666-72
pubmed: 23467600
Sex Transm Infect. 2007 Dec;83(7):558-66
pubmed: 17932126
Sex Transm Infect. 2018 Aug;94(5):340-345
pubmed: 29748180
PLoS One. 2018 Mar 2;13(3):e0193577
pubmed: 29499042
Int J STD AIDS. 2015 Mar;26(4):251-6
pubmed: 24855131
Lancet. 1999 Nov 20;354(9192):1776-81
pubmed: 10577639
AIDS. 1993 Jan;7(1):95-102
pubmed: 8442924
Diagn Microbiol Infect Dis. 2012 Sep;74(1):49-53
pubmed: 22727836

Auteurs

Nigel Garrett (N)

Centre for the AIDS Programme in South Africa (CAPRISA), Durban, South Africa.
School of Nursing and Public Health, Discipline of Public Health Medicine, University of KwaZulu-Natal, Durban, South Africa.

Nireshni Mitchev (N)

Department of Microbiology, University of KwaZulu-Natal, Durban, South Africa.

Farzana Osman (F)

Centre for the AIDS Programme in South Africa (CAPRISA), Durban, South Africa.

Jessica Naidoo (J)

Centre for the AIDS Programme in South Africa (CAPRISA), Durban, South Africa.

Jienchi Dorward (J)

Centre for the AIDS Programme in South Africa (CAPRISA), Durban, South Africa.

Ravesh Singh (R)

Department of Microbiology, University of KwaZulu-Natal, Durban, South Africa.
National Health Laboratory Service, Durban, South Africa.

Hope Ngobese (H)

Prince Cyril Zulu Communicable Disease Centre, eThekwini Municipality, Durban, South Africa.

Anne Rompalo (A)

Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.

Koleka Mlisana (K)

Department of Microbiology, University of KwaZulu-Natal, Durban, South Africa.
National Health Laboratory Service, Durban, South Africa.

Adrian Mindel (A)

Centre for the AIDS Programme in South Africa (CAPRISA), Durban, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH